Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
This study has been terminated.
(See termination reason in detailed description)
Sponsor:
Novo Nordisk
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00322257
First received: May 3, 2006
Last updated: July 9, 2012
Last verified: July 2012
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
Detailed Description:
This trial is conducted in the United States of America (USA) and Canada. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin determir in Type 1 Diabetes.
Condition | Intervention | Phase |
---|---|---|
Diabetes Diabetes Mellitus, Type 1 |
Drug: inhaled human insulin Drug: insulin detemir Drug: insulin aspart |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
Official Title: | Inhaled Mealtime Insulin With the AERx® iDMS Versus Subcutaneous Injected Insulin Aspart Both in Combination With Insulin Detemir in Type 1 Diabetes: A 104 Week, Open-Label, Multicenter, Randomised, Parallel Trial (Followed by a Twelve-Week Re-Randomised Extension) To Investigate Safety and Efficacy |
Resource links provided by NLM:
Further study details as provided by Novo Nordisk:
Primary Outcome Measures:
- HbA1c [ Time Frame: After 52 weeks ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Body weight [ Time Frame: after 52 weeks ] [ Designated as safety issue: No ]
- Antibodies [ Time Frame: after 52 weeks ] [ Designated as safety issue: No ]
- Hypoglycemia [ Time Frame: For the duration of the trial ] [ Designated as safety issue: No ]
- Insulin doses [ Time Frame: For the duration of the trial ] [ Designated as safety issue: No ]
- Pulmonary Function [ Time Frame: For the duration of the trial ] [ Designated as safety issue: No ]
- Fasting plasma glucose [ Time Frame: after 52 weeks ] [ Designated as safety issue: No ]
Enrollment: | 596 |
Study Start Date: | May 2006 |
Study Completion Date: | April 2008 |
Primary Completion Date: | April 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Experimental: A |
Drug: inhaled human insulin
Treat-to-target dose titration scheme, inhalation.
Drug: insulin detemir
Injection s.c., 50% of daily dose
Other Name: Levemir, NN304
|
Active Comparator: B |
Drug: insulin detemir
Injection s.c., 50% of daily dose
Other Name: Levemir, NN304
Drug: insulin aspart
Treat-to-target dose titration scheme, injection s.c.
|
Detailed Description:
The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Type 1 diabetes
- HbA1c less than or equal to 11%
- Body mass index (BMI) less than or equal to 40.0 kg/m2
Exclusion Criteria:
- Total daily insulin dosage more than 100 IU or U/day.
- Current smoking or smoking within the last 6 months
- Impaired hepatic or renal function
- Cardiac problems
- Uncontrolled hypertension
- Current proliferative retinopathy or maculopathy requiring acute treatment
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00322257
Show 82 Study Locations
Show 82 Study Locations
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: | Gabriele Sonnenberg | Novo Nordisk |
More Information
Additional Information:
No publications provided
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 16, 2012
Additional Information:
No publications provided
Responsible Party: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00322257 History of Changes |
Other Study ID Numbers: | NN1998-2076 |
Study First Received: | May 3, 2006 |
Last Updated: | July 9, 2012 |
Health Authority: | Canada: Health Canada United States: Food and Drug Administration |
Additional relevant MeSH terms:
Diabetes Mellitus Diabetes Mellitus, Type 1 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases |
Insulin aspart Insulin Insulin, Long-Acting Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on October 16, 2012